Skip to main content
. 2021 Mar 19;5:PO.20.00321. doi: 10.1200/PO.20.00321

FIG A2.

FIG A2.

Comparison between molecular response evaluable and unevaluable cohorts. Response and outcomes for the 50 patients with a molecular response evaluable cohort (baseline Max-VAF > 0.3%) compared to the 16 patients in the unevaluable cohort (baseline Max-VAF < 0.3%). One patient in the evaluable cohort was lost to follow-up. (A) Baseline Max-VAF detected and RECIST response at 6 months. Kaplan-Meier survival curves using a cutoff baseline Max-VAF of > 0.3% for (B) progression-free survival and (C) overall survival. HR, hazard ratio; VAF, variant allele fraction.